Patents by Inventor Mark Furber

Mark Furber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Compounds 010
    Publication number: 20110201581
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 11, 2011
    Publication date: August 18, 2011
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Piperidines as chemokine modulators (CCR)
    Patent number: 7956070
    Abstract: Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: June 7, 2011
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Peter Cage, Mark Furber, Elizabeth Kinchin, Christopher Luckhurst, Aaron Rigby
  • Compounds 010
    Patent number: 7902181
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: March 8, 2011
    Assignee: AstraZeneca AB
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Chemical compounds
    Patent number: 7709500
    Abstract: The invention provides compounds of formula (I): wherein: X is CH2, O, S(O)2 or NR10; Y is a bond, CH2, NR35, CH2NH, CH2NHC(O), CH(OH), CH(NHCOR33), CH(NHSO2R34), CH2O or CH2S; Z is C(O), or when Y is a bond Z can also be S(O)2; R1 is optionally substituted aryl, optionally substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; and R2, R3, R4, R5, R6, R7 and R8, R9, R10, R32, R33, R34 and R35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.
    Type: Grant
    Filed: February 17, 2003
    Date of Patent: May 4, 2010
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber, Mark Purdie, Brian Springthorpe
  • Novel Compounds 010
    Publication number: 20090306042
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 10, 2008
    Publication date: December 10, 2009
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
    Publication number: 20090197914
    Abstract: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: March 6, 2007
    Publication date: August 6, 2009
    Inventors: Peter Cage, Mark Furber, Matthew Perry, Brian Springthorpe
  • Adamantane derivatives
    Publication number: 20090176853
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: December 4, 2008
    Publication date: July 9, 2009
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
    Publication number: 20090023733
    Abstract: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: March 6, 2007
    Publication date: January 22, 2009
    Inventors: Peter Cage, Mark Furber, Christopher Luckhurst, Matthew Perry, Brian Springthorpe
  • Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them
    Publication number: 20090012125
    Abstract: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: March 6, 2007
    Publication date: January 8, 2009
    Inventors: Peter Cage, Mark Furber, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Adamantane derivatives
    Publication number: 20080139636
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: June 20, 2007
    Publication date: June 12, 2008
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Medicaments
    Publication number: 20080108661
    Abstract: Use of a compound of formula (I): wherein: R1 is phenyl optionally substituted by halogen, cyano, C1-4 alkyl or C1-4 haloalkyl; R2 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and R3 is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of osteoarthritis or osteoarthrosis. The invention also concerns the benzenesulfonate salt of N-{3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2,3-dihydro-2-oxo-4-(trifluoromethyl)-5-thiazolecarboxamide, a process for making it, and its use in therapy (for example in treating CCR3 mediated disease states).
    Type: Application
    Filed: October 3, 2007
    Publication date: May 8, 2008
    Inventors: Peter Cage, Mark Furber, Zara Khan, Maurice Needham, Peter Newham
  • Adamantane derivatives
    Publication number: 20070082957
    Abstract: The invention provides adamantane derivatives of formula (I), a process for the their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: September 29, 2006
    Publication date: April 12, 2007
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Novel piperidines as chemokine modulators (ccr)
    Publication number: 20070054924
    Abstract: Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).
    Type: Application
    Filed: January 31, 2005
    Publication date: March 8, 2007
    Inventors: Lilian Alcaraz, Peter Cage, Mark Furber, Elizabeth Kinchin, Christopher Luckhurst, Aaron Rigby
  • Adamantane derivatives
    Patent number: 7132457
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: November 7, 2006
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
    Patent number: 6984644
    Abstract: The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: January 10, 2006
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, Andrew Cooke, Martin Cooper, David Donald, Mark Furber, Matthew Perry, Philip Thorne
  • Admantane derivatives
    Patent number: 6949539
    Abstract: The invention provides compounds of general formula (I) in which m, A, R1 and Ar have the meanings defined in the specification; a process for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: September 27, 2005
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber
  • Chemical compounds
    Publication number: 20050107428
    Abstract: The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy]wherein: X is CH2, O, S(O)2 or NR10; Y is a bond, CH2, NR35, CH2NH, CH2NHC(O), CH(OH), CH(NHCOR33), CH(NHSO2R34), CH2O or CH2S; Z is C(O), or when Y is a bond Z can also be S(O)2; R1 is optionally substituted aryl, optionally substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; and R2, R3, R4, R5, R6, R7 and R8, R9, R10, R32, R33, R34 and R35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.
    Type: Application
    Filed: February 17, 2003
    Publication date: May 19, 2005
    Inventors: Lilian Alcaraz, Mark Furber, Mark Purdie, Brian Springthorpe
  • Adamantane derivatives
    Patent number: 6881754
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 19, 2005
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Publication number: 20050049303
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: March 31, 2004
    Publication date: March 3, 2005
    Inventors: Lilian Alcaraz, Mark Furber, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Patent number: 6720452
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: April 13, 2004
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber, Timothy Luker, Michael Mortimore, Philip Thorne